Last reviewed · How we verify
Additional taking blood
At a glance
| Generic name | Additional taking blood |
|---|---|
| Sponsor | CHU de Reims |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Natural History Study for Patients With Nemaline Myopathy in Belgium (NA)
- Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis
- Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication (NA)
- Strength Training in Hospitalized Patients Using the Ghostly App: a Feasibility Study (NA)
- Next Generation Personalized Neuroblastoma Therapy (PHASE1)
- Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia (PHASE1, PHASE2)
- "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
- Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Additional taking blood CI brief — competitive landscape report
- Additional taking blood updates RSS · CI watch RSS
- CHU de Reims portfolio CI